Futura Medical PLC AGM Statement (1964R)
13 June 2018 - 4:01PM
UK Regulatory
TIDMFUM
RNS Number : 1964R
Futura Medical PLC
13 June 2018
For immediate release 13 June 2018
Futura Medical plc
("Futura" or the "Company")
AGM Statement
Futura Medical plc (AIM: FUM), the innovative healthcare company
focused on advanced transdermal technology, will hold its Annual
General Meeting ("AGM") in London later today.
Futura's Chairman, John Clarke, will make the following
statement at the AGM.
"We continue to make good progress in the development and
commercialisation of our pipeline of product opportunities.
"Our plans for our first Phase III clinical study of MED2002,
the Company's novel gel for erectile dysfunction ("ED") remain on
track and we expect to commence first patient dosing by the end of
September. The design of the study incorporates feedback from
regulators and from potential commercial partners with whom the
Company remains at an advanced stage of discussions. This feedback
has, for example, highlighted the importance of the initial
commercial target markets being men who are dissatisfied by the
slow onset of action of PDE5 inhibitors or by side-effects and
contraindications, such as those men with ED who are prescribed
nitrates.
"Completion of a significant out-licensing agreement for MED2002
remains a top priority for the Company and, whilst negotiations
proceed, we will continue to maintain the momentum in the product's
development.
"On our novel condom, CSD500, we are pleased to announce that
the product has recently received regulatory approval in Kuwait,
enabling our commercial partner in the MENA region to launch in
Kuwait as soon as practicable. This follows the previous launch in
the Kingdom of Saudi Arabia, from which repeat orders continue to
be generated. In a number of other countries, the steps towards
CSD500 launches are also underway. We continue in commercial
discussions with potential partners for CSD500 for those
territories where a commercial partner is not currently
appointed.
"On TPR100, our diclofenac gel for topical pain relief, we await
the UK regulatory dossier submission to the MHRA by Thornton &
Ross, a UK subsidiary of STADA. The completion and submission of
the dossier, which is substantial, remains a priority and we will
provide a further update once the dossier has been filed.
"Futura has a strong balance sheet, an experienced team, an
exciting product portfolio and a particularly valuable asset in
MED2002, which has the potential to be the world's fastest-acting
ED treatment. We look forward to providing further updates in the
current financial year."
For any further information please contact:
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0)1483 685 670
mail to: james.barder@futuramedical.com www.futuramedical.com
N+1 Singer (Nominated Adviser and
Broker)
Aubrey Powell / Liz Yong Tel:+44 (0) 20 7496 3000
For media enquiries please contact:
Buchanan
Mark Court / Sophie Wills / Tilly Tel: +44 (0)20 7466 5000
Abraham
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops
innovative products for consumer healthcare. The Company is
developing a portfolio of products and its strategy is to license
their manufacture and distribution to major pharmaceutical and
healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGMFKNDDPBKKNAD
(END) Dow Jones Newswires
June 13, 2018 02:01 ET (06:01 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024